359 related articles for article (PubMed ID: 29615902)
1. Drug Repositioning in Glioblastoma: A Pathway Perspective.
Tan SK; Jermakowicz A; Mookhtiar AK; Nemeroff CB; Schürer SC; Ayad NG
Front Pharmacol; 2018; 9():218. PubMed ID: 29615902
[TBL] [Abstract][Full Text] [Related]
2. Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma.
Harder BG; Blomquist MR; Wang J; Kim AJ; Woodworth GF; Winkles JA; Loftus JC; Tran NL
Front Oncol; 2018; 8():462. PubMed ID: 30406029
[TBL] [Abstract][Full Text] [Related]
3. A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells.
Dogra N; Singh P; Kumar A
Mol Neurobiol; 2024 Apr; ():. PubMed ID: 38619743
[TBL] [Abstract][Full Text] [Related]
4. Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
Jones D; Whitehead CA; Dinevska M; Widodo SS; Furst LM; Morokoff AP; Kaye AH; Drummond KJ; Mantamadiotis T; Stylli SS
Mol Cell Biochem; 2023 Jun; 478(6):1251-1267. PubMed ID: 36302993
[TBL] [Abstract][Full Text] [Related]
5. Drug and disease signature integration identifies synergistic combinations in glioblastoma.
Stathias V; Jermakowicz AM; Maloof ME; Forlin M; Walters W; Suter RK; Durante MA; Williams SL; Harbour JW; Volmar CH; Lyons NJ; Wahlestedt C; Graham RM; Ivan ME; Komotar RJ; Sarkaria JN; Subramanian A; Golub TR; Schürer SC; Ayad NG
Nat Commun; 2018 Dec; 9(1):5315. PubMed ID: 30552330
[TBL] [Abstract][Full Text] [Related]
6. A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines.
Shah AH; Suter R; Gudoor P; Doucet-O'Hare TT; Stathias V; Cajigas I; de la Fuente M; Govindarajan V; Morell AA; Eichberg DG; Luther E; Lu VM; Heiss J; Komotar RJ; Ivan ME; Schurer S; Gilbert MR; Ayad NG
Neurooncol Adv; 2022; 4(1):vdab192. PubMed ID: 35118385
[TBL] [Abstract][Full Text] [Related]
7. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
8. Drug target ranking for glioblastoma multiforme.
Saraf R; Agah S; Datta A; Jiang X
BMC Biomed Eng; 2021 Apr; 3(1):7. PubMed ID: 33902757
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
Chin C; Lunking ES; de la Fuente M; Ayad NG
Front Oncol; 2018; 8():521. PubMed ID: 30483476
[TBL] [Abstract][Full Text] [Related]
10. Integrative rare disease biomedical profile based network supporting drug repurposing or repositioning, a case study of glioblastoma.
McGowan E; Sanjak J; Mathé EA; Zhu Q
Orphanet J Rare Dis; 2023 Sep; 18(1):301. PubMed ID: 37749605
[TBL] [Abstract][Full Text] [Related]
11. LINCS Dataset-Based Repositioning of Dutasteride as an Anti-Neuroinflammation Agent.
Luo D; Han L; Gao S; Xiao Z; Zhou Q; Cheng X; Zhang Y; Zhou W
Brain Sci; 2021 Oct; 11(11):. PubMed ID: 34827410
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral Drug Repositioning for Glioblastoma.
Rivas SR; Mendez Valdez MJ; Chandar JS; Desgraves JF; Lu VM; Ampie L; Singh EB; Seetharam D; Ramsoomair CK; Hudson A; Ingle SM; Govindarajan V; Doucet-O'Hare TT; DeMarino C; Heiss JD; Nath A; Shah AH
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730705
[TBL] [Abstract][Full Text] [Related]
13. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
14. Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme.
Behl T; Sharma A; Sharma L; Sehgal A; Singh S; Sharma N; Zengin G; Bungau S; Toma MM; Gitea D; Babes EE; Judea Pusta CT; Bumbu AG
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199460
[TBL] [Abstract][Full Text] [Related]
15. Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges.
Lee JK; Nam DH; Lee J
Oncol Lett; 2016 Feb; 11(2):1281-1286. PubMed ID: 26893731
[TBL] [Abstract][Full Text] [Related]
16. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
18. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme.
Gersey Z; Osiason AD; Bloom L; Shah S; Thompson JW; Bregy A; Agarwal N; Komotar RJ
World Neurosurg; 2019 Nov; 131():252-263.e2. PubMed ID: 31376551
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional Profiling of a Patient-Matched Cohort of Glioblastoma (IDH-Wildtype) for Therapeutic Target and Repurposing Drug Identification.
Roddy AC; McInerney CE; Flannery T; Healy EG; Stewart JP; Spence VJ; Walsh J; Salto-Tellez M; McArt DG; Prise KM
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
